Fenemal

There is no image.

Phenobarbital

Method of action: Anticonvulsant, Antiepileptic, Antispasmodic, Hypnotic, Sedative

Treatment option: Absence Seizure, Insomnia, Seizure, Convulsions, Eclampsia, Epilepsy

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fenemal

What is Fenemal? Defining its Chemical and Pharmacological Identity

Property	Description
Active ingredient	Phenobarbital (Phenobarbitone)
Form	Tablet, Elixir, Injection Solution
Pharmacological class	Barbiturate Anticonvulsant
General purpose	Control of seizures and sedation
Origin	Synthetic derivative

Fenemal is the trade name for a medicinal product containing the active substance Phenobarbital, which is chemically known as Phenobarbitone. It is classified as a long-acting barbiturate anticonvulsant and functions as a potent central nervous system (CNS) depressant.

Phenobarbital is a synthetic compound, manufactured as a derivative of barbituric acid, and is defined as a single-ingredient product. This substance is recognized for its utility in essential healthcare settings. This medication is available in multiple dosage forms, including oral preparations such as tablets and elixirs, as well as parenteral forms presented as solutions for injection. The availability of the elixir form is a key differentiating feature, often facilitating administration to pediatric and geriatric patient groups.

Phenobarbital: General Purpose and Fundamental Action

The general therapeutic purpose of the active ingredient Phenobarbital is to control and prevent recurring seizures and to induce profound sedation when medically necessary.

Its pharmacological action involves enhancing the inhibitory effects of the neurotransmitter GABA (gamma-aminobutyric acid), the principal calming chemical in the brain. Phenobarbital stabilizes nerve cell membranes, which helps suppress abnormal electrical signaling in the brain. For instance, it is typically used in a scenario requiring the long-term stabilization of brain activity to reduce the frequency of chronic generalized seizures. The medicine works to quiet overactive nerve cells, which minimizes the widespread propagation of uncontrolled electrical discharges across the central nervous system.

Regulatory References

What side effects are possible with Fenemal?

Possible Side Effects and Safety Information

The safety profile of Fenemal (Phenobarbital) is defined by its classification as a potent CNS depressant, leading to a spectrum of officially documented adverse reactions that vary by frequency and duration of exposure. This information is based strictly on regulatory sources like the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Frequency-Classified Adverse Reactions

The most frequently observed adverse reactions relate to the nervous system. Sedation and drowsiness are classified as Very Common and are typically most pronounced at the initiation of treatment, tending to lessen with continued use. Other Common nervous system effects include ataxia (lack of coordination) and nystagmus. Cognitive impairment is also a recognized common effect. Skin reactions such as a rash are Uncommon.

Adverse Reaction Category	Examples per Regulatory Labeling
Nervous System	Sedation, Drowsiness, Ataxia, Nystagmus
Skin Disorders	Allergic reactions, Stevens-Johnson Syndrome (Rare)
Blood/Bone	Megaloblastic Anemia (Rare), Decreased Bone Mineral Density

Serious Safety Considerations

The official label highlights the potential for rare but life-threatening events, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Furthermore, the risk of developing physical and psychological dependence is a critical, documented characteristic of the barbiturate class, and abrupt discontinuation is associated with the risk of severe withdrawal symptoms. Megaloblastic anemia is also documented as a rare serious adverse reaction.

Population-Specific Safety Notes

Specific populations may exhibit distinct sensitivities: children are more susceptible to paradoxical excitement or hyperactivity, while older adults face an increased risk of confusion and exaggerated sedation. Use is restricted in individuals with severe hepatic impairment due to the drug's metabolism. Long-term use in any population is associated with the risk of decreased bone mineral density.

Overdose and Emergency Response

Fenemal overdose is officially documented as a progression of severe Central Nervous System (CNS) and respiratory depression. Manifestations typically begin with profound sedation, stupor, confusion, slurred speech, uncoordinated movement (ataxia), or decreased level of consciousness. In severe cases, the clinical presentation escalates to deep coma, extremely slow or absent breathing (apnea), and extremely low blood pressure (hypotension), which can lead to circulatory collapse. These outcomes are explicitly listed as life-threatening in regulatory information.

Immediate medical attention is required in all cases of suspected overdose. Urgent medical services must be contacted when the person has collapsed, has difficulty breathing, has a seizure, or cannot be awakened, as these are signs of critical toxicity. Management is strictly symptomatic and supportive; regulatory agencies state there is no direct antidote known for barbiturates. Supportive measures documented in official prescribing information include breathing support (e.g., mechanical ventilation), maintenance of cardiovascular stability, and procedures such as activated charcoal administration or, in extreme cases, enhanced clearance methods like hemodialysis. Population-specific notes indicate that paradoxical reactions may occur in pediatric patients, while symptoms can be more profound in the elderly.

Therapeutic Uses of Fenemal

Main Uses and Benefits of Fenemal

Fenemal is a medication containing the active substance phenobarbital, which belongs to a group of medicines known as barbiturates. It is primarily utilized for its ability to reduce abnormal electrical activity in the brain.

Treatment of Epilepsy and Seizure Disorders

The primary application of Fenemal is in the management of various forms of epilepsy. It is used to prevent and control different types of seizures, including:

Generalized tonic-clonic seizures: Often referred to as grand mal seizures, these involve loss of consciousness and muscle contractions.
Focal seizures: Seizures that originate in a specific part of the brain, which may or may not affect awareness.
Status epilepticus: In certain clinical settings, it may be used to assist in managing prolonged seizure activity.

Management of Acute Anxiety and Agitation

Due to its sedative properties, Fenemal may be used for the short-term treatment of severe, acute anxiety or states of agitation. It works by depressing the central nervous system, which helps to induce a calming effect on the patient.

Other Clinical Applications

Beyond its anticonvulsant and sedative roles, Fenemal is occasionally employed in specific medical scenarios:

Neonatal Jaundice: In certain cases, it may be used to help lower bilirubin levels in newborns by stimulating liver enzyme activity.
Withdrawal Symptoms: It is sometimes utilized in controlled medical environments to manage withdrawal symptoms from other central nervous system depressants.

Key Benefits

The therapeutic objective of using Fenemal is to provide stability to the nervous system. For patients with epilepsy, the main benefit is a reduction in the frequency and severity of seizures, which can contribute to a more predictable daily life. When used for sedation, it provides a rapid onset of calm in acute situations.

Regulatory References

NIH MedlinePlus overview of Phenobarbital

Eligibility and Restrictions for Use

Fenemal (Phenobarbital) eligibility is determined by clear regulatory criteria, defining the populations who are permitted, restricted, or absolutely prohibited from using the medicine according to official government labeling.

Population Status	Official Eligibility Rule
Contraindicated	Use is prohibited in patients with a known hypersensitivity to barbiturates or a history of acute intermittent porphyria. It is also contraindicated in those with severe respiratory depression or obstructive respiratory disease, severe hepatic impairment, or severe renal impairment.
Approved Use	The medicine is approved for use in both the Adult and Pediatric populations for labeled indications.
Conditional Use	Use requires caution in older adults due to potential increased sensitivity. Patients with non-severe hepatic or renal impairment must also use the medicine under restricted conditions.
Life Stage	Fenemal is generally not recommended or contraindicated during pregnancy due to the potential for fetal harm. Use is not recommended while breastfeeding due to its excretion into breast milk.

The regulatory profile establishes distinct categories of eligibility severity, defining absolute prohibitions (Contraindicated), conditional use (Use with Caution), and general non-recommendation (Pregnancy/Lactation). This structure ensures that use is limited to approved populations while strictly excluding those with high-risk underlying conditions as stipulated in official regulatory prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fenemal's official interaction profile is dominated by its action as a potent inducer of hepatic microsomal enzymes (e.g., CYP450), which significantly accelerates the metabolism and clearance of many co-administered medicines, potentially leading to a loss of their therapeutic effect.

Key interaction domains include:

Other CNS Depressants: Co-administration with other depressant agents, such as alcohol, opioids, benzodiazepines, and other sedatives, is restricted due to the potential for additive effects resulting in profound sedation and respiratory depression.
Enzyme Substrate Medicines: Fenemal reduces the effectiveness of several therapeutic classes by enhancing their breakdown, including oral anticoagulants (e.g., warfarin, dicumarol), corticosteroids (e.g., prednisone), and hormonal contraceptives. Use with these medicines requires dose adjustments and, for contraceptives, an alternate barrier method.
Antiseizure Drugs: Fenemal's concentration is increased by co-administration with valproic acid or sodium valproate due to inhibition of its metabolism, which necessitates close monitoring of Fenemal blood levels. Concomitant use with other barbiturates or primidone is generally contraindicated.
Other Drugs: The drug can interfere with the absorption of agents like griseofulvin and reduces the efficacy of certain drugs metabolized by CYP enzymes, such as doxycycline and voriconazole.

Mechanism of Action

How Fenemal Works: Mechanism of Action

Fenemal (Phenobarbital) primarily acts as a positive allosteric modulator on the central inhibitory GABA A receptor complex. By binding to a specific site distinct from the binding site of the natural inhibitory neurotransmitter GABA (gamma-aminobutyric acid), the drug potentiates GABA's intrinsic activity. This molecular interaction increases the frequency and duration of the chloride ion channel opening. The resulting influx of negatively charged chloride ions ( Cl^-) across the neuronal membrane promotes hyperpolarization and contributes to a state of reduced neuronal excitability within the central nervous system.

Additionally, the drug influences excitatory signaling pathways, resulting in a dampening effect on neural signal propagation. This mechanism involves the indirect limitation of excitatory signal spread and the inhibition of excitatory glutamate receptors, primarily of the AMPA type. This targeted pathway interference is relevant to the regulation of high-frequency electrical activity and influences key regulatory mechanisms, resulting in altered patterns of synaptic communication.

Dosage and Administration Information

How Fenemal is used: Official Administration Guidelines

Fenemal (Phenobarbital) is administered according to clinical guidelines that define the route, dose, and frequency of use. These parameters are established to ensure consistent therapeutic application across different medical settings.

Approved Administration Routes

Route	Use Context	Key Restriction
Oral (PO)	Standard route for maintenance anticonvulsant use (tablets, elixir).	Full anticonvulsant effect may take 2–3 weeks to achieve.
Intravenous (IV)	Reserved for acute seizure states (e.g., status epilepticus).	Must be administered slowly, not exceeding 60 mg/ minute in adults.
Intramuscular (IM)	Used for acute seizures or preoperative sedation.	Injection must be deep into a large muscle mass.

Standard Dosing Regimens

Dosing recommendations vary by indication and formulation. The following regimens are commonly utilized:

Adult Anticonvulsant Maintenance (Oral): The usual daily dose is 60 mg to 200 mg, often given once daily or in divided doses.
Acute Seizure States (IV): A loading dose of 15 mg/ kg to 20 mg/ kg is administered as a single dose.
Pediatric Anticonvulsant Maintenance: Dosing is weight-based, typically 3 mg/ kg/ day to 8 mg/ kg/ day.

Special Conditions and Use Patterns

For oral forms, the medicine can be taken with or without food; however, consistency in daily intake timing is recommended. Due to the long half-life, a single daily dose is common for long-term control.

Specific populations require dose adjustment: a reduced dose is recommended for older adults and for patients with impaired liver function. Additionally, the medication must be gradually reduced (tapered) when discontinuation is necessary, to prevent acute reactions.

Recent Clinical Evidence

Evidence for Chronic Seizure Management (Epilepsy)

The use of Fenemal in conditions characterized by fluctuating or episodic manifestations like epilepsy was evaluated in research that covers several decades of observation. Studies available for this indication include Randomized Controlled Trials (RCTs) and numerous Systematic Reviews, alongside large, Long-term Observational Studies. Researchers primarily examined outcomes related to seizure patterns, such as the time to seizure remission (periods without seizures) and the reduction in seizure frequency in populations of adults and older children.

Studies report measurements observed in the studies related to seizure frequency patterns over time, with the data describing how seizure frequency evolved in the observed populations. However, certainty remains low for some aspects of chronic use. Results apply only to the populations studied, and data for certain groups, such as those newly initiating therapy, remain insufficient in current literature. Follow-up durations were limited in some of the older trials, and comparative evidence is lacking for certain head-to-head comparisons against other anti-seizure medications.

Evidence for Acute Seizure and Excitation Control

Fenemal was studied for the rapid stabilization needed during conditions associated with acute or disruptive episodes, specifically continuous seizures known as Status Epilepticus (SE). Research involves studies examining short-term or episodic symptom patterns and includes both RCTs and Prospective Cohort Studies. Research examined outcomes describing episodic or acute changes, particularly the measurement of seizure cessation and the latency observed to achieve this outcome in patients whose seizures were not stopped by initial treatments.

Studies report measurements of seizure cessation rates, describing outcomes related to episodic or acute changes. Findings indicate that seizure activity control was observed in some studies when the medication was used after other initial treatments were unsuccessful. There is a limited number of large, adequately powered RCTs that systematically compare Fenemal to other acute therapies when used for initial acute treatment in large, diverse adult populations.

Consistency and Research Gaps

Research examined specific groups, including adults with conditions involving periods of heightened symptoms such as acute alcohol withdrawal syndrome (AWS) and term and preterm infants with seizures. Research describes that the evidence quality varies across studies, largely due to the age of some trials and the different protocols used. Long-term effects are not fully established for all patient groups, and research provides context but not individual predictions about long-term symptom evolution.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Fenemal (FAQ)

Q: What should I do if I miss a dose of my Fenemal?

A: Official instructions typically state that if a dose of Fenemal (Phenobarbital) is missed, it should be taken as soon as the patient recalls. However, if it is nearly time for the next scheduled dose, the guidance typically recommends skipping the missed dose and continuing the regular schedule. It is important that patients do not take two doses at once to make up for a missed dose.

Q: I'm on birth control; does Fenemal affect its effectiveness?

A: Official product information states that Fenemal may reduce the effectiveness of hormonal contraceptives, such as birth control pills, patches, or rings. This interaction is due to how Fenemal affects the breakdown of other medicines in the body. Due to this risk, the official product label typically requires that patients consult a healthcare provider regarding the need for an alternate barrier method of contraception.

Q: Can I drink alcohol while taking Fenemal?

A: Official regulatory warnings advise against the consumption of alcohol while taking Fenemal. Alcohol is a central nervous system (CNS) depressant, and combining it with Fenemal can cause an additive depressant effect. This combination may increase effects such as severe drowsiness, dizziness, and respiratory depression.

Q: What are the signs of a Fenemal overdose?

A: Signs of a Fenemal overdose, as described in regulatory documents, may include extremely slow or shallow breathing, a weak or rapid pulse, and reduced body temperature. Other signs are severe loss of coordination and deep drowsiness that can lead to coma. The symptoms described warrant immediate medical attention, as an overdose can be fatal.

Q: How long does it take for Fenemal to start working for chronic seizures?

A: Studies and official information indicate that Fenemal is classified as a long-acting medication for chronic seizure control. The full anticonvulsant effect may not be achieved for approximately two to three weeks. This time frame is necessary for the drug to reach a consistent, stable concentration in the bloodstream.

Q: I am pregnant, can I take Fenemal?

A: Regulatory documents state that Fenemal is generally not recommended for use during pregnancy due to the drug’s potential association with a risk of fetal harm. Official warnings indicate that use during pregnancy has been connected to a higher incidence of fetal abnormalities. Infants born to women who received the drug throughout the last trimester may also experience withdrawal symptoms.

How should Fenemal be stored and disposed of?

Official Storage and Disposal Requirements

Fenemal (phenobarbital) is a controlled substance and requires specific storage and disposal protocols as defined in regulatory documents.

Requirement	Official Statement Basis
Storage Conditions	Store at room temperature, protected from excess heat and moisture.
Packaging	Keep in the original container with the lid tightly closed.
Child Safety	Store locked up and out of reach of children due to controlled substance regulations.
Disposal	Do not dispose of in household trash or down the sink. Unused or expired medication must be taken to an authorized drug take-back program or collector for safe, non-retrievable destruction.